Obesity is not a single condition with a single cause. For years, the standard approach assumed that all patients with excess weight would respond similarly to the same treatments—a calorie deficit, more exercise, or the same medication at the same dose. Weight Loss Treatment in Riyadh However, research increasingly shows that obesity is driven by distinct biological and behavioural mechanisms. A treatment that works well for one person may produce only modest results for another. This is why personalised weight loss treatment is gaining recognition as a more effective and sustainable path to better health.
Recent research has identified distinct biological subtypes of obesity. One of these is the “hungry gut” phenotype, characterised by lower production of natural appetite‑regulating hormones, faster stomach emptying, and greater hunger after meals . People with this subtype may eat normal portions but snack more frequently because they do not feel full for as long as they should.
A Mayo Clinic study found that patients with this subtype lost nearly twice as much weight on tirzepatide as those with other obesity subtypes—an average of 21.5% of their body weight over six months, compared with 11.7% . This suggests that certain medications are especially effective for specific biological profiles. Matching the right treatment to the right biology could transform how obesity is managed, moving away from trial and error toward precision medicine .
Other research highlights the role of genetics in predicting treatment response. A study published in Cell Metabolism developed a genetic risk score to predict satiation—the process that controls meal size . Patients with high scores responded better to one medication, while those with low scores did better on another . This reinforces the idea that individual biology should guide treatment selection.
Personalisation extends beyond choosing the right medication. A real‑world study of nearly 2,700 adults using an app‑based weight loss programme found that lower, individually tailored doses of semaglutide produced weight loss equivalent to full clinical trial doses—around 16.7% of baseline weight over 64 weeks . The average dose used was about 1 mg per week, far less than the 2.4 mg used in many trials .
The study combined medication with personalised behavioural support—including cognitive behavioural therapy, exercise guidance, and dietary coaching—tailored to each patient’s needs . This “treat‑to‑target” approach suggests that lower doses can be effective when supported by lifestyle changes, reducing costs and side effects while stretching medication supplies.
Medication alone does not tell the whole story. A large real‑world study of over 80,000 people on tirzepatide found that behavioural factors were among the strongest predictors of total weight loss . People who had set a personal weight goal or previously attempted structured diets lost significantly more weight . Those who lacked self‑motivation saw much more modest results .
These findings are important because they show that success depends not only on the medication prescribed but also on the patient’s readiness and engagement. This is why effective weight loss treatment should include both medical and behavioural support.
Personalisation is not a one‑time decision. A Johns Hopkins study tested an adaptive approach in breast cancer survivors with overweight or obesity . Participants started with a structured behavioural programme. Those who had not lost at least 5% of their body weight after two months were offered an anti‑obesity medication . Among those who responded early to lifestyle changes alone, the average weight loss was 10.8% over six months. Those who needed medication lost 5.1% on average—a clinically meaningful result that they likely would not have achieved without the adaptive adjustment .
This “measure, then adjust” model ensures that patients who need more support get it, while those who respond well to lifestyle changes are not over‑treated.
Technology is making personalisation more accessible. A pilot study evaluated an AI‑guided dietary supplement programme that used genetic, metabolomic, and clinical data to recommend supplements tailored to each patient’s biology . The AI‑guided group achieved 5.1% greater weight loss than a physician‑guided group and was twice as likely to achieve clinically meaningful weight loss . While this is early‑stage research, it illustrates how personalised data can improve outcomes.
Similarly, personalised nutritional advice that accounts for a person’s caloric needs, activity level, and macronutrient targets has been shown to support weight loss more effectively than generic guidance .
Obesity is a chronic, biologically driven condition. Treating it as a single disease with a single response is no longer defensible. The evidence shows that tailoring treatment—whether through medication choice, dose, behavioural support, or adaptive strategies—produces better, more sustainable results. For those seeking a Weight Loss Treatment in Riyadh, the most effective approach is one that considers your biology, your behaviour, and your goals, adjusting as you progress.
For those seeking expert guidance and customised aesthetic care, you can book an appointment consultation at the Enfield Royal Clinic.
Personalised weight loss treatment uses your biology, behaviour, and health history to select the right medication, dose, and lifestyle support for you—rather than applying a one‑size‑fits‑all approach.
Differences in biology—such as hormone levels and stomach emptying rates—affect how well these medications work. Some people respond much more strongly because the medication targets their specific biological driver.
Yes. Real‑world studies show that lower, individually tailored doses can produce weight loss equivalent to full doses when combined with behavioural and lifestyle support.
Behavioural factors—such as motivation, goal setting, and engagement with the programme—are strong predictors of success. Personalised support can help address these factors.
Many clinics are beginning to adopt personalised strategies. Approaches vary—from genetic testing and digital health tools to adaptive treatment plans. A consultation can help determine which options are suitable for your needs.
